posted on 2022-08-09, 20:40authored byJing Jie, Duo Mao, Jie Cao, Panfeng Feng, Pengxiang Yang
CAR-T-cell therapies must be expanded to obtain a large
number
of effector cells quickly, and the current technology cannot address
this challenge. A longer operational time would lose or alter the
function and phenotype of CAR-T cells in response to therapy, and
it also causes a loss in the optimal treatment time for patients.
At present, lower survival time and homing efficiency reduce the antitumor
effect of CAR-T in vivo. But nobody has solved these two issues in
one system, which has a similar microenvironment of lymphoid organs
to activate/expand cell delivery for immunotherapy. Here, we generated
artificial, customized immune cell matrix scaffolds based on a self-assembling
peptide to preserve and augment the cell phenotype in light of the
characteristics of CAR-T. The all-in-one nanoscale matrix scaffolds
reduced the processing time of CAR-T to 3 days and resulted in over
a 10-fold increase compared with the traditional protocol. The cells
were combined to modulate mechanotransduction and chemical signals,
and the mimic matrix scaffolds showed optimal stiffness and adhesive
ligand density, thereby accelerating CAR-T-cell proliferation. Meanwhile,
engineering CAR-T-secreted intrinsic PD-1 blocking single-chain variable
fragments (scFv) further increased cell proliferation and cytotoxicity
by resisting the self and tumor microenvironment in a paracrine and
autocrine manner. Local delivery of CAR-T cells from the scaffolds
significantly enabled long-term retention, suppressed tumor growth,
and increased infiltration of effector T cells compared with traditional
CAR-T treatment. The application of bioengineering and genetic engineering
approaches has led to the development of rapid culture environments
that can control matrix scaffold properties for CAR-T-cell and cancer
immunotherapies.